{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:05:16Z","timestamp":1784099116930,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Recurrent retroperitoneal sarcoma remains a significant therapeutic challenge. Recurrence does not always indicate treatment failure but reflects different tumor biologies with diverse implications for local and systemic management. This review proposes a biology-based framework for recurrent RPS that incorporates histology, disease-free interval, tumor growth kinetics, multifocality, resectability, functional reserve, and therapeutic proportionality. Histological subtype significantly influences recurrence patterns. Well-differentiated liposarcoma often follows a chronic local-regional course, where multiple surgeries can offer long-term control. In contrast, leiomyosarcoma more commonly shows early systemic spread, which diminishes the benefit of repeated local treatments. Disease-free interval and tumor growth rate are important dynamic indicators that improve prognosis and assist in timing treatment. Complete resection is essential for a meaningful survival benefit, but resectability alone does not justify surgery. Radiotherapy and systemic therapy serve complementary roles, mainly in local control, biological modulation, and palliation. Prognostic tools and nomograms aid in initial risk assessment, but are most valuable when combined with dynamic factors that reflect tumor behavior. Future advancements will rely on clinically relevant biomarkers, adaptive predictive models, personalized surveillance, recurrence-focused clinical trials, and shared decision-making based on meaningful patient benefits.<\/jats:p>","DOI":"10.3389\/or.2026.1846525","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:09:49Z","timestamp":1784095789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent retroperitoneal sarcoma: beyond resectability toward a biology-based therapeutic framework"],"prefix":"10.3389","volume":"20","author":[{"given":"Dorian Yarih","family":"Garcia-Ortega","sequence":"first","affiliation":[{"name":"Surgical Oncology. Skin, Soft Tissue & Bone Tumors Department, National Cancer Institute","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montiel","family":"Jim\u00e9nez Fuertes","sequence":"additional","affiliation":[{"name":"Unidad de Sarcomas, Servicio de Cirug\u00eda General y Digestiva, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Damian","family":"Quildrian","sequence":"additional","affiliation":[{"name":"\u2060Sarcoma and Melanoma Unit, Soft Tissue Tumors Department, Angel H Roffo Institute of Oncology, University of Buenos Aires","place":["Buenos Aires, Argentina"]},{"name":"Sarcoma and Melanoma Unit, General Surgery Department, Buenos Aires British Hospital","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Devaud","sequence":"additional","affiliation":[{"name":"Cirug\u00eda Oncologica y HPB, Cl\u00ednica Universidad de los Andes","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","article-title":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group","volume":"263","author":"Gronchi","year":"2016","journal-title":"Ann Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice Guidelines","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/curroncol30030209","article-title":"Management of recurrent retroperitoneal sarcoma","volume":"30","author":"Jolissaint","year":"2023","journal-title":"Curr Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cncr.20269","article-title":"Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution","volume":"100","author":"Gronchi","year":"2004","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1245\/s10434-014-3643-4","article-title":"Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?","volume":"21","author":"Tseng","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1078-0432.CCR-18-2700","article-title":"Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG","volume":"25","author":"Raut","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ejso.2020.08.030","article-title":"Recurrent retroperitoneal sarcomas: clinical outcomes of surgical treatment and prognostic factors","volume":"47","author":"Tropea","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/jso.24919","article-title":"Current principles of surgery for retroperitoneal sarcomas","volume":"117","author":"Fairweather","year":"2018","journal-title":"J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/SLA.0000000000002250","article-title":"Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the transatlantic RPS working group","volume":"267","author":"MacNeill","year":"2018","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/curroncol30010039","article-title":"Morbidity and mortality after surgery for retroperitoneal sarcoma","volume":"30","author":"Ruff","year":"2022","journal-title":"Curr Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma (STRASS)","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/SLA.0000000000006098","article-title":"New sarculator prognostic nomograms for patients with primary retroperitoneal sarcoma: case volume does matter","volume":"279","author":"Callegaro","year":"2024","journal-title":"Ann Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/SLA.0b013e3181b2468b","article-title":"Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule","volume":"250","author":"Park","year":"2009","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12957-019-1728-z","article-title":"Overcoming a travel burden to high-volume centers for treatment of retroperitoneal sarcomas is associated with improved survival","volume":"17","author":"Schmitz","year":"2019","journal-title":"World J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/bjs.6994","article-title":"Surgical management of primary retroperitoneal sarcoma","volume":"97","author":"Strauss","year":"2010","journal-title":"Br J Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ejso.2022.06.008","article-title":"Management of recurrent retroperitoneal sarcomas","volume":"49","author":"Siew","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1432900","DOI":"10.3389\/fonc.2024.1432900","article-title":"Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review","volume":"14","author":"Garcia-Ortega","year":"2024","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.3390\/curroncol30030211","article-title":"Surveillance post surgery for retroperitoneal soft tissue sarcoma","volume":"30","author":"Whitaker","year":"2023","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109704","DOI":"10.1016\/j.ejso.2025.109704","article-title":"Management strategies following recurrence of resected retroperitoneal sarcoma: a 10-year observational study","volume":"51","author":"Young","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103778","DOI":"10.1016\/j.eclinm.2026.103778","article-title":"Early recurrence and prognosis in patients undergoing resection of primary retroperitoneal sarcoma: an international, retrospective cohort study","volume":"92","author":"Gronchi","year":"2026","journal-title":"EClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ejso.2021.10.013","article-title":"Cytoreductive surgery with HIPEC in peritoneal sarcomatosis: a systematic review and meta-analysis","volume":"48","author":"Wong","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12256","DOI":"10.1038\/s41598-026-42442-x","article-title":"Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models","volume":"16","author":"Huang","year":"2026","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/ejso.2001.1166","article-title":"Dutch soft tissue sarcoma group. Locoregional recurrence of retroperitoneal soft tissue sarcoma: second chance of cure for selected patients","volume":"27","author":"van Dalen","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ejso.2008.11.003","article-title":"Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival","volume":"35","author":"Lehnert","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1575260","DOI":"10.3389\/fonc.2025.1575260","article-title":"Multiple surgical interventions improve survival in locally recurrent retroperitoneal sarcoma: a retrospective cohort analysis","volume":"15","author":"Yan","year":"2025","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1073274820983028","DOI":"10.1177\/1073274820983028","article-title":"Definitive radiotherapy in non-resectable or residual retroperitoneal sarcomas","volume":"28","author":"Sobiborowicz","year":"2021","journal-title":"Cancer Control"},{"key":"B29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/COC.0000000000001000","article-title":"Stereotactic body radiation therapy for sarcoma pulmonary metastases","volume":"46","author":"Asha","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"42639","DOI":"10.18632\/oncotarget.9476","article-title":"Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy","volume":"7","author":"Fan","year":"2016","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11864-017-0465-1","article-title":"Image-guided thermal ablative therapies in the treatment of sarcoma","volume":"18","author":"Thompson","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jso.24933","article-title":"Systemic therapy in retroperitoneal sarcoma management","volume":"117","author":"Constantinidou","year":"2018","journal-title":"J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1199292","DOI":"10.3389\/fphar.2023.1199292","article-title":"Chemotherapeutic drugs for soft tissue sarcomas: a review","volume":"14","author":"Tian","year":"2023","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"French sarcoma group. doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.32795","article-title":"European organization for research and treatment of cancer soft tissue and bone sarcoma group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the european organization for research and treatment of cancer soft tissue and bone sarcoma group","volume":"126","author":"D'Ambrosio","year":"2020","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","article-title":"A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma","volume":"5","author":"Roland","year":"2024","journal-title":"Nat Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"106977","DOI":"10.1016\/j.ejso.2023.07.003","article-title":"Long-term quality of life after resection of retroperitoneal soft tissue sarcoma","volume":"49","author":"Willis","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1245\/ASO.2005.03.016","article-title":"Effectiveness of palliative procedures for intra-abdominal sarcomas","volume":"12","author":"Yeh","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/cancers17061040","article-title":"Unlocking the potential of ctDNA in sarcomas: a review of recent advances","volume":"17","author":"Aiyer","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1846525\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:09:50Z","timestamp":1784095790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1846525\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":45,"alternative-id":["10.3389\/or.2026.1846525"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1846525","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1846525"}}